Portfolio News

Media Coverage

Interviews and presentations

NetScientific Present at IMC
PlayPlay
Netscientific at MELLO Events
PlayPlay
previous arrow
next arrow
NetScientific Present at IMC
Netscientific at MELLO Events
previous arrow
next arrow

News from ProActive Investors

● Below a list of latest news on NetScientific covered by ProActive Investors

NetScientific follows its money as investee company announces plans to raise US$45mln
NetScientific follows its money as investee company announces plans to raise US$45mln
NetScientific: City broker provides thumbs up following PDS funding round
NetScientific: City broker provides thumbs up following PDS funding round
NetScientific receives enthusiastic response to fundraising
NetScientific receives enthusiastic response to fundraising
NetScientific on the rise again after PDS cancer trial
NetScientific on the rise again after PDS cancer trial
NetScientific’s ProAxsis to validate and commercialise AstraZeneca’s Coronavirus vaccine assay
NetScientific’s ProAxsis to validate and commercialise AstraZeneca’s Coronavirus vaccine assay
NetScientific PLC: WH Ireland sees significant potential upside
NetScientific PLC: WH Ireland sees significant potential upside
NetScientific business unit eyes opportunities to significantly boost top revenues
NetScientific business unit eyes opportunities to significantly boost top revenues
NetScientific hails the potential of investee company’s cancer immunotherapy
NetScientific hails the potential of investee company’s cancer immunotherapy
PlayPause
NetScientific follows its money as investee company announces plans to raise US$45mln
NetScientific: City broker provides thumbs up following PDS funding round
NetScientific receives enthusiastic response to fundraising
NetScientific on the rise again after PDS cancer trial
NetScientific’s ProAxsis to validate and commercialise AstraZeneca’s Coronavirus vaccine assay
NetScientific PLC: WH Ireland sees significant potential upside
NetScientific business unit eyes opportunities to significantly boost top revenues
NetScientific hails the potential of investee company’s cancer immunotherapy
previous arrow
next arrow

Podcasts

● Interview with Dr Ilian Iliev on Hardman & Co

News and Research